title: [Safety of meningococcal A and C vaccine. Data from the Spanish drug surveillance system. Meningococcal Vaccine Research Group of the Spanish System of Drug Surveillance].
abstract: OBJECTIVE
  Data on meningococcal vaccines safety are scanty. In 1997 several vaccination campaign took place in Spain. Thus, this situation was used to improve our knowledge about the safety profile of this vaccine.
  
  
  METHODS
  An inquiry was carried out to the Regional Centers of the Spanish Pharmacovigilance System to know the number of vaccinated people and the type and number of suspected cases of adverse reactions.
  
  
  RESULTS
  There were 133 identified cases of suspected adverse reactions associated with meningococcal A and C vaccine until June 1st, 1998. Most of them affected the skin (25,3%) or nervous system (similar proportion). Those of allergic reactions accounted for 35,2%. Two cases were considered as severe, although they were resolved without secuelae.
  
  
  CONCLUSIONS
  Serious risks were not detected. The Spanish Pharmacosurveillance System as an epidemiological surveillance resource has been useful to know the safety problems associated with antimeningococcal vaccine in the community.
authors.forename: F
authors.initials: F
authors.lastname: de Abajo
authors.forename: A
authors.initials: A
authors.lastname: Alvarez Requejo
authors.forename: I
authors.initials: I
authors.lastname: Ayani
authors.forename: J A
authors.initials: JA
authors.lastname: Carrillo
authors.forename: A
authors.initials: A
authors.lastname: Carvajal
authors.forename: J R
authors.initials: JR
authors.lastname: Castillo
authors.forename: T
authors.initials: T
authors.lastname: Cuchi
authors.forename: C
authors.initials: C
authors.lastname: Esteban Calvo
authors.forename: A
authors.initials: A
authors.lastname: Figueras
authors.forename: J
authors.initials: J
authors.lastname: García del Pozo
authors.forename: S
authors.initials: S
authors.lastname: González
authors.forename: M
authors.initials: M
authors.lastname: González Ruiz
authors.forename: F T
authors.initials: FT
authors.lastname: Herrero
authors.forename: A
authors.initials: A
authors.lastname: Hidalgo
authors.forename: C
authors.initials: C
authors.lastname: Giménez Guillén
authors.forename: H
authors.initials: H
authors.lastname: Khalid
authors.forename: M A
authors.initials: MA
authors.lastname: Martínez
authors.forename: M
authors.initials: M
authors.lastname: Madurga
authors.forename: M M
authors.initials: MM
authors.lastname: Martins
authors.forename: M M
authors.initials: MM
authors.lastname: Mallén
authors.forename: I M
authors.initials: IM
authors.lastname: de Diego
authors.forename: G
authors.initials: G
authors.lastname: Martín-Serrano
authors.forename: D
authors.initials: D
authors.lastname: Montero
authors.forename: M
authors.initials: M
authors.lastname: Navarro
authors.forename: C
authors.initials: C
authors.lastname: Pedrós
mesh_terms: D000293:Adolescent; D000328:Adult; D000367:Age Factors; D001428:Bacterial Vaccines / Q000009:adverse effects*; D002648:Child; D002675:Child, Preschool; D003627:Data Interpretation, Statistical; D005260:Female; D006801:Humans; D007223:Infant; D008297:Male; D022401:Meningococcal Vaccines; D009345:Neisseria meningitidis / Q000276:immunology*; D011358:Product Surveillance, Postmarketing; D013030:Spain
chemical_list: D001428:Bacterial Vaccines; D022401:Meningococcal Vaccines